Preeclampsia is a leading cause of maternal and fetal/neonatal mortality and morbidity worldwide. The early identification of patients with an increased risk for preeclampsia is therefore one of the most important goals in obstetrics. The availability of highly sensitive and specific physiologic and biochemical markers would allow not only the detection of patients at risk but also permit a close surveillance, an exact diagnosis, timely intervention (e.g. fetal lung maturation), as well as simplified recruitment for future studies looking at therapeutic medications and additional prospective markers. Today, several markers may offer the potential to be used, either singly or more preferably in combination analysis, as predictors or diagnostic tools. I have decided to assess the usefulness of uric acid as biochemical marker of maternal, fetal and neonatal outcome in patient with preeclampsia at delivery. Uric acid assessment can easily be performed, cheap, readily available, and acceptable to most patients in this study. The study showed that preeclampsia with associated hyperuricaemia was associated with increased small for gestational age (SGA) babies (p<0.001), preterm deliveries (p<0.001), low birth weight (p<0.001) and admission in special care baby unit (SCBU) (p<0.001). There were also increased adverse maternal outcomes in this group of patient including increased medically indicated caesarean section (p<0.001), maternal seizure (p<0.001), thrombocytopenia (p<0.019), severe headache (p<0.001), proteinuria (P<0.001) and visual disturbances (p<0.046). This emphasis the usefulness of this easily performed, cheap, readily available and acceptable predictive test of fetal